US · Healthcare · Biotechnology
EPS came in at 0.03 against a street estimate of -11.50 — a beat of 100.3%.
Analysts rate Lakefront Biotherapeutics NV a hold (2 buy, 3 hold, 1 sell out of 6) with an average price target of $30.16.
| Fund | Stake |
|---|---|
| TANG CAPITAL MANAGEMENT LLC | 5.77% |
| Madison Avenue Partners, LP | 5.25% |
| Prosight Management, LP | 3.11% |
| EcoR1 Capital, LLC | 2.54% |
| Ameriprise Financial Inc | 1.94% |
| Renaissance Technologies Corp | 0.62% |
| BlackRock Inc | 0.52% |
| Point72 Asset Management, L.P. | 0.41% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 126,322 ordinary shares between October 05, 2026 and October 09, 2026. • The shares were bo | 2026-10-13 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Bank of America Corporation’s combined Lakefront Biotherapeutics voting rights and equivalent financial instruments fell below the | 2026-10-09 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 117,437 ordinary shares between September 28, 2026 and October 02, 2026. • The shares were | 2026-10-06 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 106,060 ordinary shares between September 21, 2026, and September 25, 2026, under its repurc | 2026-09-29 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 108,679 of its own shares between September 14, 2026 and September 18, 2026. • The shares w | 2026-09-23 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics repurchased 125,517 ordinary shares between September 07, 2026 and September 11, 2026. • The shares wer | 2026-09-15 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Lakefront Biotherapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission for September 2026. • The filing | 2026-09-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Lakefront Biotherapeutics NV repurchased 132,014 ordinary shares between August 31, 2026 and September 04, 2026 under its buyback | 2026-09-08 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lakefront Biotherapeutics NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.